Media CoveragePlease click on any item below to read more. If you wish to reproduce any items from The Tennessean newspaper (Nashville, TN), please cite as follows: "Reprinted with permission from The Tennessean" and include the date of publication. No other changes are permitted. FDA's OK Will Propel Lynch into Sales Push Tricky Terrains TV Interview with BioMimetic Therapeutics CEO Dr. Samuel Lynch BioMimetic: PMA in Progress "It is an exciting and busy time for us" Dan Ryan Interview with BMTI's Jim Monsor at BIO Atlanta 2009 Direct Hit: BioMimetic Achieves Enrollment Target Synthetic 'Dust' May Replace Bone Grafts BioMimetic Scoring Again BioMimetic's PDGF-Based Bone Therapy Wins in Trial Small Cap Summer Blockbusters Technology Separates It From Field BioMimetic Ends First Trading Day at $8.25 After First Product Approval, BioMimetic Seeks $50M IPO Filing Seeks Area's First Biotech IPO Discovery Emerges as Dental Product for Bone Restoration BioMimetic's PDGF Product Approved In Dental Indication |